New Zealand took a significant step in February when it expanded prescribing authority for ADHD medication, allowing general practitioners to prescribe drugs previously restricted to specialists. The policy aimed to reduce wait times and increase treatment access across the country, particularly in rural and underserved communities where psychiatrists are scarce.
Yet months after the rollout, implementation reveals stubborn barriers that undercut the reform's promise.
Training gaps plague the system. Many GPs lack confidence diagnosing ADHD in adults, and fewer still understand the nuances of medication management for the condition. New Zealand's medical schools have historically devoted minimal curriculum time to ADHD across the lifespan. Without mandatory training programs or clear clinical guidelines tailored to primary care, GPs face uncertainty when prescribing. Some practices have adopted internal protocols. Others proceed cautiously, essentially recreating the bottleneck the policy intended to remove by referring complex cases back to specialists.
Cost remains a wall for many patients. While the medication itself may become cheaper through GP prescribing, diagnostic assessments still fall primarily to private providers in New Zealand's mixed healthcare model. A comprehensive ADHD evaluation costs hundreds to thousands of dollars out-of-pocket. Public waiting lists for specialist assessment stretch beyond a year in major cities. Families with resources can jump the queue. Those without cannot.
Geographic disparities persist. Urban GPs with larger patient populations can justify investing in training and building referral networks with psychologists and psychiatrists. Rural practitioners operate alone or in very small teams, with limited access to specialist consultation and educational resources. A GP in Northland faces different constraints than one in Auckland.
The policy also created an unintended consequence: some specialists have stepped back from public sector work, knowing GPs now handle routine prescribing. This concentrates complex cases in private practice, which families must navigate independently.
Data on uptake remain incomplete. The Ministry of Health has not released comprehensive figures on how many GPs are actually prescribing ADHD medication or how wait times have shifted post-February. Without this evidence, policymakers cannot identify where implementation falters or where patients slip through gaps.
Advocates and clinicians broadly support the reform's direction. Centralizing all ADHD treatment in specialist hands simply does not work in a country New Zealand's size. GPs represent the logical point of entry for early identification and ongoing management. The rule change was necessary.
But necessity and sufficiency are not the same thing. Expanding prescribing authority without accompanying investment in workforce training, equitable access to diagnosis, and regional service coordination leaves reform half-finished.
Closing these gaps requires faster action. Health authorities should fund mandatory ADHD training modules for GPs, embed clear diagnostic and prescribing guidelines in primary care systems, and establish regional networks linking GPs to specialist backup. Public funding for initial assessment through primary care would bypass the private cost barrier. Collecting and publishing real-time wait time and prescribing data would expose failures quickly.
The February policy opened a door. What happens next depends on whether New Zealand commits resources to walk through it.